OTHER MED DERM PRODUCTS CONFIRMATORY PATENT ASSIGNMENTWW
`AGREEMENT
`
`THIS OTHER MED DERM PRODUCTS CONFIRMATORY PATENT ASSIGNMENT
`AGREEMENT (this “Assignment”) is dated as of October 10, 2018 (“Effective Date”), and is
`made among Allergan, Inc., a Delaware limited liability, on behalf of itself and its Affiliates that
`__
`have any right, title, or interest in, to or under the Patents (as defined below) (collectively, the
`“Assignors”), and Almirall, LLC, a Pennsylvania limited liability company (the “Assignee”).
`
`WHEREAS, pursuant to, and upon the terms and conditions of, agreements including the
`Business Acquisition Agreement dated as of August 3, 2018 (the “Bill of Sale”), by and between
`Allergan Sales, LLC and Allergan Pharmaceuticals International Limited, and Almirall, Inc,
`Assignors have agreed to sell, convey, assign and transfer to Assignee, and Assignee has agreed
`to accept certain rights, including beneficial ownership of Assignors’ worldwide right, title and
`interest in, to and under the patents and patent applications, utility models and industrial designs
`set forth in Schedule A (attached hereto), and all applications and registrations therefor, together
`with all non-provisionals, reissuances, continuations, continuations-in-part, divisions, revisions,
`extensions and reexaminations with respect
`thereto, and any other applications and patents
`sharing a claim of priority therewith (hereinafter referred to as “Patents”); and
`
`WHEREAS, each Assignor desires to confirm and perfect its transfer and assignment to
`Assignee, and Assignee is desirous of confirming and perfecting the transfer and assignment of
`all of Assignor’s worldwide right, title and interest in, to and under said Patents and in, to and
`under the inventions represented thereby.
`
`NOW, THEREFORE, effective as of the date hereof, each Assignor, for good and
`valuable consideration, the receipt and sufficiency of which are hereby acknowledged, does
`hereby sell, convey, assign and transfer to Assignee, if and to the extent that it may not already
`have done so by virtue of the OTHER MED DERM PRODUCTS PATENT ASSIGNMENT
`AGREEMENT dated September 20, 2018 among Allergen Sales LLC, its Affiliates and Aqua
`Pharmaceuticals, LLC, all of Assignor’s worldwide right, title and interest in, to and under the
`Patents,
`together with all rights to:
`(i) claim priority in all countries in accordance with
`international law, (ii) collect royalties and proceeds in connection with any of the foregoing, (iii)
`apply for, prosecute, and seek patents throughout the world in respect of any inventions to the
`extent fully supported by the Patents, and (iv) sue for past, present or future infringement of said
`Patents worldwide together with all claims for damages for reason of past, present or future
`infringement of said Patents, and the right to sue for and collect the same for Assignee’s own use
`and enjoyment, all to be held and enjoyed by said Assignee, its successors and assigns, as fully
`and entirely as the same would have been held and enjoyed by such Assignor had this
`Assignment not been made.
`
`Each Assignor hereby requests the Commissioner of Patents and Trademarks and the
`corresponding entities or agencies in any other applicable countries to record Assignee as the
`assignee and owner of the Patents, including any continuations, divisions, continuations—in part,
`reissues, reexaminations or extensions thereof, and to issue any and all
`letters patent of the
`United States thereon to Assignee, as assignee of the entire right, title and interest in, to and
`
`Amneal v. Almirall, |PR2018—00608
`ALMIRALL EX. 2001 - 1/4
`
`Amneal v. Almirall, IPR2018-00608
`ALMIRALL EX. 2001 - 1/4
`
`
`AGREEMENT
`
`THIS OTHER MED DERM PRODUCTS CONFIRMATORY PATENT ASSIGNMENT
`AGREEMENT (this “Assignment”) is dated as of October 10, 2018 (“Effective Date”), and is
`made among Allergan, Inc., a Delaware limited liability, on behalf of itself and its Affiliates that
`__
`have any right, title, or interest in, to or under the Patents (as defined below) (collectively, the
`“Assignors”), and Almirall, LLC, a Pennsylvania limited liability company (the “Assignee”).
`
`WHEREAS, pursuant to, and upon the terms and conditions of, agreements including the
`Business Acquisition Agreement dated as of August 3, 2018 (the “Bill of Sale”), by and between
`Allergan Sales, LLC and Allergan Pharmaceuticals International Limited, and Almirall, Inc,
`Assignors have agreed to sell, convey, assign and transfer to Assignee, and Assignee has agreed
`to accept certain rights, including beneficial ownership of Assignors’ worldwide right, title and
`interest in, to and under the patents and patent applications, utility models and industrial designs
`set forth in Schedule A (attached hereto), and all applications and registrations therefor, together
`with all non-provisionals, reissuances, continuations, continuations-in-part, divisions, revisions,
`extensions and reexaminations with respect
`thereto, and any other applications and patents
`sharing a claim of priority therewith (hereinafter referred to as “Patents”); and
`
`WHEREAS, each Assignor desires to confirm and perfect its transfer and assignment to
`Assignee, and Assignee is desirous of confirming and perfecting the transfer and assignment of
`all of Assignor’s worldwide right, title and interest in, to and under said Patents and in, to and
`under the inventions represented thereby.
`
`NOW, THEREFORE, effective as of the date hereof, each Assignor, for good and
`valuable consideration, the receipt and sufficiency of which are hereby acknowledged, does
`hereby sell, convey, assign and transfer to Assignee, if and to the extent that it may not already
`have done so by virtue of the OTHER MED DERM PRODUCTS PATENT ASSIGNMENT
`AGREEMENT dated September 20, 2018 among Allergen Sales LLC, its Affiliates and Aqua
`Pharmaceuticals, LLC, all of Assignor’s worldwide right, title and interest in, to and under the
`Patents,
`together with all rights to:
`(i) claim priority in all countries in accordance with
`international law, (ii) collect royalties and proceeds in connection with any of the foregoing, (iii)
`apply for, prosecute, and seek patents throughout the world in respect of any inventions to the
`extent fully supported by the Patents, and (iv) sue for past, present or future infringement of said
`Patents worldwide together with all claims for damages for reason of past, present or future
`infringement of said Patents, and the right to sue for and collect the same for Assignee’s own use
`and enjoyment, all to be held and enjoyed by said Assignee, its successors and assigns, as fully
`and entirely as the same would have been held and enjoyed by such Assignor had this
`Assignment not been made.
`
`Each Assignor hereby requests the Commissioner of Patents and Trademarks and the
`corresponding entities or agencies in any other applicable countries to record Assignee as the
`assignee and owner of the Patents, including any continuations, divisions, continuations—in part,
`reissues, reexaminations or extensions thereof, and to issue any and all
`letters patent of the
`United States thereon to Assignee, as assignee of the entire right, title and interest in, to and
`
`Amneal v. Almirall, |PR2018—00608
`ALMIRALL EX. 2001 - 1/4
`
`Amneal v. Almirall, IPR2018-00608
`ALMIRALL EX. 2001 - 1/4
`
`
`
`under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal
`representatives.
`
`Any counterpart may be executed by facsimile or PDF signature and such facsimile or
`PDF signature shall be deemed an original. The terms and conditions of this Assignment shall
`inure to the benefit of Assignee, its successors, assigns and other legal representatives, and shall
`be binding upon Assignor, its successors, assigns and other legal representatives. Except to the
`extent that U.S. federal law preempts state law with reSpect to the matters covered hereby, this
`Assignment shall be governed by and construed in accordance with the laws of the State of New
`York, without giving effect to the principles of conflicts of law thereof.
`
`the undersigned has executed this Other Med Derm
`IN WITNESS WHEREOF,
`Products Confirmatory Patent Assignment Agreement
`as
`of
`the
`date
`first
`set
`forth
`above.
`
`ASSIGNORS:
`
`ALLERGAN, Inc, on behalf of itself and
`its Affiliates that have any right, title, or
`interest in, to or under the Patents
`
`
`
`Amneal v. Almirall, |PR2018—00608
`ALMIRALL EX. 2001 - 2/4
`
`Amneal v. Almirall, IPR2018-00608
`ALMIRALL EX. 2001 - 2/4
`
`
`
`
`
`DZ<mZOFHwOmEOUHZmém<D<EZOmm<D%mZOmm<QA<meOH
`
`
`
`
`
`”~0demmDMOMmQOEmmz
`
`
`
`Q72mzoEmonEoum2m€m<3\%omfimQ72mzomnao122mgI
`
`
`
`
`
`
`
`
`
`94¢mZOE—mOmEOU.mqu<m<Q<\m:/~0mm<flQZ<MZOmndeA<UEOH
`
`4aswofim
`
`mwnfimm
`
` QZ<
`
`
`
`mZOHHHmOEZOUmZm—énwdflfimZOmmdQQ7?NmZOmm<QA<OEOH
`”NEGI Bantam
`
`
`
`mz<mzoEmongoumzfigmmfimzomm4mQ72mzomrja€038IIMMmamas:m3.
`LOWMmEHWmDMOMmQOEmE222m
`
`
`EEEEIEI
`
`2834
`
`072mZOFHmOmEQOmqu<m<Q<EZOmm<QQZ<mZOmm<Q39050:“.335%:wma“3mSENSE:mmmNwohwm
`AimQmNEHMOHmbmommammDMOEmDOEHmEanm
`
`
`
`
`
`
`
`M2980
`
`
`
`
`
`mZOELmOmEOUm2mém¢fl<\m20mm<mQZ<mZOmmacdiUEOHqumimmEDEm9396.3}:new9323w>HQwDQ24.AfixmQMNELMMOELVmomMm—EFmmDMOMmQOEHmELnA25.5.
`
`
`
`
`
`
`
`92¢mZOFHmOmEOUmZmifigfizOmafidQZ<mZOmm<QA<UEOHSonata2?w9.uZ
`
`mOmMmEHmmbmOmmQOEHmDZ(1n2mmom§n<00m3
`
`
`
`”HOmEmELELmmDMGRmDOEm—Enn2wfiumnm20m3QZ<mZOPHmOmEOUmZmflwfiijfimeOanQQ72mZOmeQéuEOHI.“new:QmFmva.U
`
`
`
`
`
`_ocmvfim200mgQ72mZOELmOmEOU3,512meQfimZmeJmQQ24mZOmmwwDM<UEOHI'mfioQomFSmwofimIII
`
`mOMmmmHmmDmommQOIHmS,n
`
`
`
`
`
`
`
`
`
`>U<UEmmm>§§<mfiou
`
`
`
`
`
`
`
`.mgmqu?mZU<ES?mij—MmmeUmmAOnameMmSHuang:8szwqumoawUEExmm32Hfiemm20mm<flm0WEEEWQOHQ24
`
`
`
`
`
`
`
`
`
`
`
`
`UZHmDmDQOAD>MZU<MOHZmEh/xgm0mDOEdeII2oQSZ:3.c.Q.mZOFHmOEOUmZOmOQQn.nmmEumxm0mmm3mQuack
`
`
`
`
`
`
`awo‘moimmmE<m<mEOUII20m:$8I.*mgowmdrWZU<ES)mméEmmHZMUWMAOHEmemm>HAD?necnmfiwhl3:533m32“gmmZOmm<QmoEHEEmAOHQZ<
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`AgmfivHUSUOHQGCONU<OHwouflmhOHM"ugh:mfioflmofigmwWEN3593mmH230:<.AgmvwofifiobmQEONO<OHUgh—0M»
`
`
`
`
`
`
`
`
`
`Amneal v. Almirall, |PR2018—00608
`ALMIRALL EX. 2001 - 3/4
`
`Amneal v. Almirall, IPR2018-00608
`ALMIRALL EX. 2001 - 3/4
`
`
`
`
`
`
`w»Rmxmw.
`
`
`
`
`
`A<UEOH07mm:mgwqbspmZU<”HOHzg<mmrwm0mQOEmE
`
`
`
`
`
`
`
`mZOMHHmOEOUmZOmnfiwQ
`
`
`
`mZOELHwOnHEOUmZOmm<Q
`
`
`
`
`
`A<UEOHUZHmDm§<043>mZU<m0HZWEH<WMPMOwQOEmEZ
`
`
`
`AdwUEOHUZHmDma<015>W754“HOHZ§H<Em0mQOEHmE
`
`
`
`
`
`
`
`mZOmeOEOUmZOmnde
`
`IIIEI
`
`Amneal v. Almirall, |PR2018—00608
`ALMIRALL EX. 2001 - 4/4
`
`Amneal v. Almirall, IPR2018-00608
`ALMIRALL EX. 2001 - 4/4
`
`
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
